Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative

Mayo Clinic Proceedings

Volumn 83, Issue 10, 2008, Pages 1131-1135

  Gertz, Morie A ^a   Ansell, Stephen M ^a   Dingli, David ^a   Dispenzieri, Angela ^a   Buadi, Francis K ^a   Elliott, Michelle A ^a   Gastineau, Dennis A ^a   Hayman, Suzanne R ^a   Hogan, William J ^a   Inwards, David J ^a   Johnston, Patrick B ^a   Kumar, Shaji ^a   Lacy, Martha Q ^a   Leung, Nelson ^a   Micallef, Ivana N M ^a   Porrata, Luis F ^a   Schafer, Barbara A ^a   Wolf, Robert C ^a   Litzow, Mark R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEASIBILITY STUDY; FEMALE; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTPATIENT CARE; RISK ASSESSMENT; AMBULATORY SURGERY; AUTOTRANSPLANTATION; COMPARATIVE STUDY; FOLLOW UP; METHODOLOGY; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME; UNITED STATES;

AGED; AMBULATORY SURGICAL PROCEDURES; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MINNESOTA; MULTIPLE MYELOMA; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 54049084554     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.10.1131     Document Type: Article

References (20)

1. Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients <60 vs ≥60 years of age. Bone Marrow Transplant. 2003;32(12):1135-1143.
2. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am. 1997;11(1):133-146.
3. Moreau P, Hullin C, Garban F, et al; Intergroupe Francophone du Myelome group. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood. 2006 Jan 1;107(1):397-403. Epub 2005 Sep 6.
4. Mishra V, Vaaler S, Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol. 2003; 25(3):179-184.
5. Mishra V, Andresen S, Brinch L, et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant. 2005;35(12):1149-1153.
6. Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer. 2008;112(5):1096-1105.
7. Moellering RC Jr, Graybill JR, McGowan JE Jr, Corey L. Antimicrobial resistance prevention initiative - an update: proceedings of an expert panel on resistance. Am J Infect Control. 2007;35(9, suppl):S1-S23.
8. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006;119(6, suppl 1):S11-S19.
9. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol. 1999;104(1):131-137.
10. Stella-Holowiecka B, Czerw T, Holowiecka-Goral A, Giebel S, Wojnar J, Holowiecki J. ?2-Microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Transplant Proc. 2007;39(9):2893-2897.
11. Olivieri A, Capelli D, Montanari M, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant. 2001;27(11):1189-1195.
12. Kassar M, Medoff E, Seropian S, Cooper DL. Outpatient high-dose melphalan in multiple myeloma patients. Transfusion. 2007;47:115-119.
13. Johnson W, Kerridge I, Milton C, et al. Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma. Aust J Adv Nurs. 2006;23(4):34-39.
14. Curtiss FR. Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm. 2006;12(7):570-577.
15. Mackay M. Practical experience with bed occupancy management and planning systems: an Australian view. Health Care Manag Sci. 2001;4(1):47-56.
16. Moores KG. Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever. Am J Health Syst Pharm. 2007;64(7):717-722.
17. Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant. 1998;21(9):927-932.
18. Morabito F, Martino M, Stelitano C, et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica. 2002;87(11):1192-1199.
19. Limat S, Woronoff-Lemsi MC, Milpied N, et al; Groupe Ouest Est d'etude des Leucemies et Autres Maladies du Sang (GOELAMS). Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in frontline therapy. Eur J Cancer. 2000;36(18):2360-2367.
20. Mazza P, Secondo E, Palazzo G, et al. Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital. Haematologica. 1999;84(2):142-149.